Introduction
============

In Turkey, gastric cancer is the second most common cause of cancer-related mortality in men, and the fourth most common cause in women.[@B1] It is very important to assess the presence or absence of metastases to establish appropriate treatment plans for gastric cancer. Gastric cancer generally metastasizes to the peritoneal surfaces, liver, and distant lymph nodes; metastasis to the spleen, adrenal glands, ovaries, lung, brain, or even the skin has also been noted frequently. There is limited data on the frequency and clinical significance of bone marrow metastasis in gastric cancer. Bone marrow metastases are frequently observed with solid tumors and these may negatively affect patient survival. Malignancies of the prostate, breast, lung, kidney, thyroid, and stomach are the most common neoplasms that may metastasize and involve the bone marrow.[@B2],[@B3],[@B4],[@B5],[@B6],[@B7],[@B8],[@B9],[@B10] There are limited published data from the Far East about gastric cancer with bone marrow involvement. In the last 4 years, 420 patients with gastric cancer were admitted at our clinics, of which 245 had metastatic cancer. Of these, only 5 patients had bone marrow metastasis. We have evaluated the characteristics of these patients and reviewed the literature.

Case Report
===========

We evaluated 5 (2%) patients with bone marrow metastasis out of 245 patients with advanced gastric cancer. The median age was 45 years (range, 22\~55), which was lower than that of the overall population of gastric cancer patients. All patients were male; 3 patients had signet-ring cell type, 1 had undifferentiated type, and 1 had tubular type tumor, according to the World Health Organization classification. Four patients had primary tumors located in the corpus and 1 patient had neoplasm of the cardia. The most common sites of synchronous metastasis in gastric cancer patients with bone marrow involvement were the bone (4/5 patients), followed by the liver (3/5 patients). All patients with bone marrow metastasis were diagnosed on the basis of bone marrow biopsy reports, and all patients had cytopenia at the time of admission. Three patients were diagnosed with bone marrow metastasis and gastric cancer synchronously. One patient had peritoneal metastasis at the time of diagnosis, and bone marrow metastasis developed 5 months later. Only 1 patient had recurrence with bone and bone marrow metastasis after curative surgery and adjuvant chemoradiotherapy at the 32nd month of diagnosis. Two patients received chemotherapy after the diagnosis of bone marrow metastasis. The median duration of survival after the diagnosis of bone marrow involvement was 47 days. The range of survival duration after diagnosis of bone marrow metastasis was 20\~53 days among the 4 patients who died; 1 patient was alive at 61 days after diagnosis. Clinicopathological features of the 5 patients are summarized in [Table 1](#T1){ref-type="table"}. Only 2 patients underwent chemotherapy. Unfortunately, 1 patient died after the first cycle, and the other patient died after the second cycle of treatment.

Four patients had both anemia and thrombocytopenia, and 1 patient had only thrombocytopenia. All patients had elevated levels of alkaline phosphatase (ALP) with a median value of 615 U/L (normal range, 40\~150 U/L), and lactate dehydrogenase (LDH) with a median of 628 U/L (normal range, 125\~220 U/L). However, no patient developed hypercalcemia, although 4 patients had bone metastases. Laboratory findings are summarized in [Table 2](#T2){ref-type="table"}.

Discussion
==========

Bone marrow infiltration with malignant cells is frequently observed in patients with solid organ malignancies. Carcinomatosis of the bone marrow can originate from the primary prostate, lung, or breast carcinoma,[@B2],[@B3],[@B4],[@B5],[@B6],[@B7],[@B8],[@B9],[@B10],[@B11] and rarely from gastric carcinoma.[@B3] There is limited data regarding the incidence and clinical significance of bone marrow metastasis in gastric carcinoma. This case series is one of the largest in the literature compared to other case series reported from the Far East. Kim et al.[@B12] reported the prevalence of bone morrow metastasis to be 0.024, which was confirmed by bone marrow biopsy reports. Kusumoto et al.[@B13] reported 9 gastric cancer patients with bone marrow metastases, and concluded that all patients had more aggressive histopathology (signet ring cell or poor differentiated) and were younger than patients without bone marrow metastasis. They also reported an elevation of ALP and/or LDH levels in gastric cancer patients with bone marrow involvement, and 6 of 9 patients had disseminated intravascular coagulopathy.

In gastric cancer cases, bone metastasis is usually rare compared to liver and peritoneal metastasis. In the 5 cases of gastric cancer with bone marrow involvement reported here, 4 patients had bone metastasis, which was consistent with reports from published literature. In the study by Kwon et al.[@B14] that included gastric cancer patients with bone marrow involvement, the incidences of metastases to the bone, lung, and liver were 57% (15/26), 11% (3/269), and 3.8% (1/26), respectively. Of the 2,150 patients with advanced cancer in the study by Ahn et al.,[@B15] there were 19 patients (0.9%) with bone metastases; however, another study revealed a higher incidence (13.4%, 33/246 patients) among autopsy cases.[@B16] In both series, bone metastasis was associated with poorly differentiated histology. All these findings suggest that there may be a relationship between bone and bone marrow metastasis, and possibly between poor differentiation and unusual metastatic sites, including the bone and bone marrow. Kong et al.[@B17] reported that there were 193 (0.96%) patients with pulmonary metastases among 20,197 patients with advanced gastric cancer; further, 34 (17%) of the patients with lung metastasis also had bone metastasis and 11 (5.7%) patients had bone marrow metastasis as well as lung metastasis. Besides, 58% of the patients had poorly differentiated or signet ring cell histopathology.

Chemotherapy is known to prolong survival as compared to best supportive care (BSC), for the management of advanced gastric carcinoma.[@B18] However, these reports in published literature were limited to patients with adequate bone marrow function; in other words, patients with bone marrow involvement were excluded. The incidence of bone marrow metastases in gastric cancer patients is low; therefore, the clinical features and optimal treatment options for such patients has not yet been established. In the present study, 4 patients died approximately within 2 months after the diagnosis of bone marrow metastasis. In the study by Kusumoto et al.,[@B13] the median survival was only 3 months in the chemotherapy group and 2 months in the BSC group, with borderline significance in gastric cancer patients with bone marrow metastasis. Kwon et al.[@B14] published the largest case series in 2011. In that report, 15 patients received palliative chemotherapy and 10 patients received BSC. The median survival was 11 days in the BSC group compared to 121 days in the palliative chemotherapy group (P\<0.001). Because of the lack of prospective studies of gastric cancer patients with bone marrow metastases, an optimal chemotherapy regimen is still unknown.

Bone marrow metastases in gastric cancer patients are characterized by aggressive histology and a younger age of onset. They are diagnosed on the basis of bone marrow biopsy findings and treated like cases of metastasis to other sites. Unfortunately, patients have poor prognosis, characterized by short survival times.

###### 

Clinicopathological features of gastric carcinoma patients with bone marrow metastases
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WHO = World Health Organization classification; BSC = best supportive care; CDDP = cisplatin; 5-FU = 5-fluorouracil.

###### 

Laboratory findings of gastric carcinoma patients with bone marrow metastases at the time of diagnosis
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Normal range: LDH at diagnosis, 125\~220 U/L; ALP at diagnosis, 40\~150 U/L; Calcium level at diagnosis, 8.4\~10.2 mg/dl. LDH = lactate dehydrogenase; ALP = alkaline phosphatase.
